Substituted heterocyclic ethers and their use in CNS disorders

Details Substituted heterocyclic ethers and their use in CNS disorders Substituted heterocyclic ethers and their use in CNS disorders

2008-01-25

2011-12-06

O'Dell, David K (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C544S242000, C544S333000, C514S318000

Reexamination Certificate

active

08071778

ABSTRACT:
The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.

REFERENCES:
patent: 5620989 (1997-04-01), Harrison et al.
patent: 5760018 (1998-06-01), Baker et al.
patent: 7098203 (2006-08-01), Wu et al.
patent: 7138423 (2006-11-01), Wu et al.
patent: 2006/0019944 (2006-01-01), Wu et al.
patent: 2006/0019992 (2006-01-01), Wu et al.
patent: 2006/0223830 (2006-10-01), De Nanteuil et al.
patent: 2007/0249607 (2007-10-01), Degnan et al.
patent: 0 337 167 (1994-08-01), None
patent: WO 03/078376 (2003-09-01), None
patent: WO 2004/004722 (2004-01-01), None
patent: WO 2004/022539 (2004-03-01), None
patent: WO2004/083171 (2004-09-01), None
George A. Patani “Bioisosterism: A Rational Approach in Drug Design” Chemical Reviews 1996, 96, 3147-3176.
Wermuth, Camille G. “Molecular Variation Based on Isosteric Replacements” in Chapter 13, The Practice of Medicinal Chemistry, Academic: 1996.
Nakamura, Toshio “Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.” Bioorganic & Medicinal Chemistry Letters 2004, 14, 333-336.
Li, Bing et. al. “N-(Arylacetyl)-biphenylalanines as Potent VLA-4 Antagonists” Bioorganic & Medicinal Chemistry Letters 2002, 12, 2141-2144.
Gentsch, C., et al., “Anxiolytic effect of NKP608, a NK-1-receptor antagonist, in the social investigation test in gerbils”,Behavioural Brain Research, 133 (2002) 363-368.
Kramer, M.S., et al., “Distant Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors”,Science, 281 (1998) 1640-1645.
Papp, M., et al., “The NK-1 receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats”,Behavioural Brain Research, 115 (2000) 19-23.
Rosen, T.J., et al., “Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist”,Bioorganic Med. Chem. Lett., 8 (1998) 281-284.
Stevenson, G.I., et al., “4,4-Disubstituted Piperidines: A New Class of NK1Antagoinists”,J. Med. Chem., 38 (1995) 1264-1266.
Stevenson, G.I., et al., “4,4-Disubstituted Piperidine High-Affinity NK1Antagoinists: Structure-Activity Relationships and in Vivo Activity”,J. Med. Chem., 41 (1998) 4623-4635.
Varty, G.B., et al., “The Gerbil Elevated Plus-mase II: Anxiolytic-like Effects of Selective Neurokinin NK1 Receptor Antagonists”, Neuropsychopharmacology, 27 (2002) 371-379.

Affiliated with

Also associated with

Rating

Substituted heterocyclic ethers and their use in CNS disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted heterocyclic ethers and their use in CNS disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted heterocyclic ethers and their use in CNS disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4311163